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A REVIEW OF GENETIC POLYMORPHISMS IN THE RECEPTORS FOR 
GONADOTROPIC AND SEX HORMONES IN POLYCYSTIC OVARY 
SYNDROME 
SARA RUDOLPH 
ABSTRACT 
 Polycystic ovary syndrome is a complex, heterogeneous disease that affects 5-
10% of reproductive-aged women. It is characterized by clinical or biochemical 
hyperandrogenism, oligo-anovulation, and polycystic ovary morphology. Instigating 
endocrine findings include aberrantly rapid gonadotropin-releasing hormone pulsatile 
secretion, elevated luteinizing hormone, sub-optimal levels of follicle-stimulating 
hormone, and hyperandrogenism. Metabolic symptoms are also present including 
hyperinsulinemia, insulin resistance, and dyslipidemia. These endocrine and metabolic 
findings are also accompanied by ovarian dysfunction and improper folliculogenesis. 
Because aberrant functioning of the hypothalamic-pituitary-gonadal axis is central to the 
pathophysiology of polycystic ovary syndrome, it is beneficial to examine it for 
abnormalities. Polycystic ovary syndrome has been shown to have both genetic and 
environmental components. Its strong genetic component has been demonstrated in twin 
studies, family association studies, candidate gene studies, and genome-wide association 
studies. Previous genome-wide association studies have found many candidate genes 
including those for DENND1A (differentially expressed in normal and neoplastic cells 
domain containing 1A), THADA (thyroid adenoma-associated protein), FSHR (follicle-
stimulating hormone receptor), and LHR (luteinizing hormone receptor). This, together 
  vii
with the central endocrine abnormalities, prompted this review on polymorphisms of 
receptors of the hypothalamic-pituitary-gonadal axis, including those for gonadotropin-
releasing hormone, luteinzing hormone, follicle-stimulating hormone, estrogen, and 
progesterone, as well as anti-müllerian hormone. Studies on single-nucleotide 
polymorphisms of these receptors were found on PubMed, Web of Science, and Google 
Scholar and subsequently analyzed. Many different single-nucleotide polymorphisms 
were studied, but only a handful of them have been subjected to repeated studies. Only 
rs2293275 of the luteinizing hormone receptor and rs2349415 of the follicle-stimulating 
hormone receptor, both at 2p16.3, were found to have a possible role in the etiology of 
polycystic ovary syndrome, but all eight were found to have a possible phenotypic role: 
rs13405728, rs2293275, and rs4539842 of the luteinizing hormone receptor; rs6165, 
rs6166, rs2268361, and rs2349415 of the follicle-stimulating hormone receptor; and 
rs2002555 of the anti-müllerian hormone receptor. The limitations most affecting the 
results of these studies include small sample sizes, heterogeneous study populations, lack 
of generalizability due to ethnicity, and lack of control or adjustment for confounders. It 
is necessary to develop a standardized study protocol and separate polycystic ovary 
syndrome patients based on phenotype in order to obtain stronger results in the future. 
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INTRODUCTION 
 
Background  
Polycystic ovary syndrome (PCOS) affects anywhere from 5-15% of women 
worldwide depending on diagnosis criteria and ethnicity (Bozdag et al., 2016; Goodarzi 
et al., 2005; Michelmore et al., 1999; Tehrani et al., 2011). Since its discovery in 1935—
then named Stein-Leventhal Syndrome after its discoverers—it has baffled and fascinated 
physicians, researchers, and patients alike (Stein et al., 1935). Three main issues 
characterize PCOS: ovulatory disorder, biochemical or clinical androgen excess, and 
polycystic ovarian morphology. These symptoms tend to be non-uniform and 
heterogeneous in nature. Instigating endocrine symptoms include aberrantly rapid 
gonadotropin-releasing hormone (GnRH) pulsatile secretion, elevated luteinizing 
hormone (LH), sub-optimal levels of follicle-stimulating hormone (FSH), and subsequent 
hyperandrogenism. Metabolic symptoms are also present as hyperinsulinemia, insulin 
resistance, and dyslipidemia. These endocrine and metabolic symptoms are also 
accompanied by ovarian dysfunction and improper folliculogenesis (Dumesic et al., 
2015). 
PCOS patients tend to be overweight or obese, and also have an increased risk of 
metabolic syndrome and type II diabetes (Dumesic et al., 2015). There is also evidence 
for an increased lifetime risk of cardiovascular disease and cancer even after adjustment 
for body mass index (BMI), but existing studies are conflicting and lack statistical power 
(Garg et al., 2016; Merz et al., 2016; Shen et al., 2015). Interestingly, psychiatric 
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symptoms such as depression, anxiety, eating disorders, schizophrenia, bipolar disorder, 
borderline personality disorder, attention-deficit hyperactivity disorder (ADHD), autism 
spectrum disorder (ASD) have also been found to exist at greater prevalence among 
PCOS patients compared to the general population (Cesta et al., 2016; Trisno et al., 2016; 
Kerchner et al., 2009). 
 
Clinical Presentation and Diagnosis 
 The etiology of PCOS is complex and largely misunderstood, partly due to the 
heterogeneity of symptoms and presentation. However, there is evidence for the 
heritability of PCOS and a familial inheritance pattern (Kahsar-Miller et al., 1998) as 
well as environmental factors including exposure to androgens in utero (Dumesic et al., 
2014; Xu et al., 2014). Due to the complex interplay of symptoms and etiology, PCOS is 
challenging to diagnose in a clinical setting. PCOS typically presents at puberty when 
ovarian dysfunction becomes apparent in the way of oligoovulation or anovulation, which 
is clinically defined as irregular or nonexistent ovulation or menses (Dumesic et al., 
2015). Because puberty is a time when a young woman’s hormone levels are already in 
flux, the symptoms may go unnoticed by both patient and physician. Furthermore, it has 
been shown that establishment of cycle regularity can take anywhere from one to three 
years after menarche in healthy females, with 65% of adolescents achieving 10 or more 
menstrual periods per year at one year post-menarche and 90% achieving 10 or more 
menstrual periods per year at three year post-menarche (Legro et al., 2000b). 
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To complicate this further, three sets of diagnosis criteria exist for identification 
of PCOS: NIH, Rotterdam, and AE-PCOS Society. The National Institute of Health 
(NIH) criteria, developed in 1990, require both chronic oligo-anovulation and either 
clinical or biochemical hyperandrogenism for diagnosis of PCOS. These criteria are 
generally considered to be most restrictive since diagnosis via this method yields the 
lowest prevalence estimates (Bozdag et al., 2016). Developed jointly in 2003 by the 
European Society of Human Reproduction and Embryology and the American Society 
for Reproductive Medicine (ESHRE/ASRM), the Rotterdam consensus criteria require 
two of the following three symptoms: oligo-anovulation, clinical or biochemical 
hyperandrogenism, and polycystic ovary (PCO) morphology (Bozdag et al., 2016). Thus, 
these criteria allow for slightly more flexibility in diagnosis to mirror the heterogeneity of 
PCOS symptoms but also lead to an apparent increase in prevalence (Rashidi et al., 
2014). A third set of criteria, developed by the Androgen Excess and PCOS (AE-PCOS) 
Society in 2006, requires clinical or biochemical hyperandrogenism plus either oligo-
anovulation or PCO (Bozdag et al., 2016). However, this creates issues in research since 
the freedom to diagnose patients by the NIH, Rotterdam, or AE-PCOS criteria inevitably 
yields a more diverse and heterogeneous population of affected women. This creates 
difficulties when attempting to assemble large groups of similar individuals for study 
because furthermore, each set of diagnosis criteria comes with a different estimate of 
PCOS prevalence (Bozdag et al., 2016). 
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Genetic Basis for Study 
The heritability of PCOS has been demonstrated through twin studies and family 
association studies. In a large study of over 3,000 twin pairs, Vink et al. (2006) found that 
PCOS correlated strongly between monozygotic twins, although Jahanfar et al. (1995) 
had previously failed to demonstrate an association among 34 twin pairs. Kahsar-Miller 
et al. (1998) found that sisters of PCOS women have a 40% risk of developing PCOS 
themselves and also provided evidence for a single autosomal gene inheritance with 
variable phenotypes. However, the specific method of genetic inheritance is still to be 
elucidated. 
There are four methods of studying heritability: twin studies, family association 
studies, candidate gene studies, and genome-wide association studies (GWAS). There 
have been very few twin studies of PCOS, and the results are conflicting as previously 
mentioned (Jahanfar et al., 1995; Vink et al., 2006). Family association studies are much 
more numerous and are able to study a wide variety of genetic alterations among family 
members with similar genomes including things like polymorphisms in the gene for 
estrogen receptor (Silva et al., 2015) as well as clustering of male-pattern baldness in 
families with a history of PCOS (Legro, 2000a; Lenarcik et al., 2011).  
Candidate gene studies of PCOS involve the analysis of single-nucleotide 
polymorphisms (SNPs) known to contribute to the pathophysiology. Candidate gene 
studies are usually smaller than GWAS and provide a more focused analysis but require a 
point of reference and prior evidence in order to select the candidate genes. These are 
numerous and have included genes for sex hormone-binding globulin (SHBG), FSH 
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receptor, insulin receptor, fat mass and obesity-association gene (FTO), and many others 
(Dumesic et al., 2015). GWAS are the most comprehensive method of study and involve 
scanning the entire genome of study participants for polymorphisms and abnormalities 
associated with the disease of interest. GWAS have the advantage of providing a 
comprehensive analysis of associated genetic abnormalities within the DNA, as the name 
“genome-wide” indicates, but are also time consuming, expensive, and yield an 
overwhelming amount of information that may or may not truly be associated with the 
disease of interest. Because of this, they are most useful as a starting point rather than a 
method for assessing true association. Regardless, previous GWAS for PCOS have found 
many candidate genes. Genes with the strongest evidence for association with PCOS 
include those for DENND1A (differentially expressed in normal and neoplastic cells 
domain containing 1A), THADA (thyroid adenoma-associated protein), INSR (insulin 
receptor), FSHR, LHR, and C9orf3 (chromosome 9 open reading frame 3), among others 
(Chen et al., 2011; Cui et al., 2012; Shi et al., 2012; Unsal et al., 2009). However, most 
GWAS have been performed among Han Chinese women so it is uncertain whether or 
not these susceptibility loci exist in all ethnicities. 
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Figure 1.1 Methods of studying the heritability of diseases 
 
Relevance of the HPG Axis as a Focus of Genetic Study 
 The hypothalamic-pituitary-gonadal (HPG) axis is a prime candidate for genetic 
studies on PCOS because it is one of the main sources—if not the single main source—of 
physiological derangement in the disease. Alterations in normal GnRH secretion 
ultimately affect the entire axis via altered LH and FSH secretion from the pituitary, 
which leads to an altered secretion of estrogen and progesterone. Because molecular 
signaling through receptor binding is the primary method by which hormones on this axis 
elicit responses, it is relevant to examine any polymorphisms within the receptors for 
GnRH, LH, FSH, estrogen, and progesterone. 
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Specific Aims 
 The goal of this literature review is to analyze the contributions of genetic 
polymorphisms in the receptors for gonadotropin-releasing hormone (GnRH), luteinizing 
hormone (LH), follicle-stimulating hormone (FSH), estrogen, progesterone, and anti-
müllerian hormone (AMH). The primary focus will be on SNPs, although occasional 
insertion or deletion mutations will also be considered. Analysis of the literature of 
polymorphisms of these receptors will lead to a better understanding of their contribution 
to the etiology and pathophysiology of PCOS, as well as create a foundation from which 
to move forward to future research. 
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PUBLISHED STUDIES 
 
 A search on PubMed was performed using the MeSH term “polycystic ovary 
syndrome” on February 1, 2017, which returned 11,844 results. From these results, 
articles with any mention or variation of “DNA,” “gene,” “mutation,” “polymorphism,” 
“SNP,” “haplotype,” “variant,” “methylation,” “epigenetic,” “mRNA,” “transcript,” or 
“miRNA” within the title was selected. This produced 752 results. From these, articles 
were further isolated if they contained the terms “gonadotropin-releasing hormone 
receptor,” “GnRH receptor,” “luteinizing hormone receptor,” “LH receptor,” “follicle-
stimulating receptor,” “FSH receptor,” “anti-müllerian hormone receptor,” “AMH 
receptor,” “estrogen receptor,” or “progesterone receptor.” This produced a total of 105 
articles. Selecting studies that focused only on genetic mutations further narrowed results. 
35 articles were selected for final analysis. 
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RESULTS AND ANALYSIS 
 
 
Gonadotropin-Releasing Hormone (GnRH) Receptor 
Gonadotropin-releasing hormone (GnRH)—more specifically, GnRH-1—is a 
decapeptide that is synthesized in and secreted from the neurons in the hypothalamus. 
The gene encoding GnRH-1 is located on the short arm of chromosome 8 (8p21.2) and 
has been found to be highly conserved among vertebrates (Millar et al., 2004). The 
regulation of GnRH secretion is complex, involving neural, endocrine, and environmental 
inputs ultimately leading to the continuous pulsatile release of GnRH from the 
hypothalamus. Furthermore, the rate of GnRH secretion from the hypothalamus is highly 
dependent on the current phase of the female menstrual cycle, with a less frequent 
secretion rate during the follicular phase and a more frequent secretion rate during the 
luteal phase (Barbieri et al., 2014). The primary function of GnRH is to bind to and elicit 
a response from the GnRH type I receptor in order to release the gonadotropins LH and 
FSH (Strauss et al., 2014, p. 7). 
The gonadotropin-releasing hormone type I receptor (GnRHR) is a G-protein coupled 
receptor (GPCR) embedded in the plasma membrane of gonadotropes (gonadotropin-
producing cells) of the anterior pituitary gland. The gene encoding the GnRHR is located 
on the long arm of chromosome 4 (4q13.2) and consists of four exons and three introns. 
The receptor operates via a phosphatidylinositol-calcium second-messenger system upon 
binding of GnRH at the cell surface, which ultimately leads to the release of LH and FSH 
from the anterior pituitary gland. Interestingly, the balance between LH versus FSH 
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secretion is affected by the nature of the pulsatile GnRH secretion, with slower GnRH 
secretory pulses leading to an increased secretion of FSH and more rapid GnRH secretory 
pulses leading to an increased secretion of LH (Gross et al., 1987). The GnRH receptor is 
responsible for decoding and translating the variable secretion rate of GnRH, although 
the mechanism through which this occurs is still under investigation. Candidate 
mechanisms include signal pathways such as ERK (extracellular signal-regulated kinase) 
(Armstrong et al., 2010) and Ca2+/NFAT (nuclear factor of activated T-cells) (Armstrong 
et al., 2009). It is thought that there is a dose-response relationship between the amount of 
GnRH binding to the receptor and the aforementioned signal pathways, which leads to 
different ratios of LH and FSH being secreted from the anterior pituitary gland. 
Naturally, aberrant GnRH hormone or receptor function can create issues in LH and 
FSH secretion, and in turn estrogen and progesterone secretion. Since PCOS 
pathophysiology is primarily centered on an aberrant HPG axis, it is necessary to 
examine mutations of the GnRH receptor. Defects in the gene for GnRHR are known to 
cause hypogonadotropic hypogonadism, so it follows that point mutations may affect the 
action of the receptor in PCOS. 
To date, there are three studies on mutations of the GnRHR among PCOS patients, 
the parameters and findings of which are listed below in Tables 1.1, 1.2, and 1.3. The 
first—Cohen et al. (1999)—investigated whether activating or inactivating mutations 
have a role in PCOS etiology. The presence of insertions or deletions within the exonic 
regions of the GnRHR gene was analyzed among Caucasian PCOS patients in a small 
candidate gene study. No insertions or deletions were found in either cases or controls. 
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Ten years later, Valkenburg et al. (2009) published the results of a large candidate 
gene study among Dutch Caucasian women that investigated SNPs of the GnRH, FSH, 
and LH receptor genes. The selected GnRHR polymorphism under study was rs6185, a 
SNP in exon 1 that results in an amino acid change at position 16 from tryptophan to 
serine. No differences were found in the distribution of either alleles or genotypes 
between cases and controls, but the presence of the Ser16 allele was found to have a 
negative correlation with testosterone and insulin levels, free androgen index, and follicle 
count among PCOS cases (P ≤ 0.01, P ≤ 0.01, P ≤ 0.01, and P = 0.05, respectively). 
Li et al. (2011) set out to determine the association between variation in the GnRHR 
gene and levels of thyroid and insulin functionality in PCOS patients. The candidate gene 
study was of moderate size including 261 PCOS cases and 687 controls, and all 
participants were of Han Chinese origin. The selected SNP was rs1038246 within the 3’-
untranslated region (UTR) of the GnRHR gene, which results in a T to G transition. The 
G allele of this SNP was found to correlate positively with TSH and insulin levels both 
one and two hours after a glucose load among PCOS cases (P = 0.007, P = 0.018, P = 
0.009, respectively). No significant differences in allele or genotype distributions were 
found between cases and controls. 
The overarching implications of the current results lean towards little genotypic, and 
presumably etiologic, association but possible phenotypic contribution. Cohen et al. 
(1999), Valkenburg et al. (2009), and Li et al. (2011) found no genotype or allele 
distribution differences, and Valkenburg et al. and Li et al. found only a few phenotypic 
associations. However, this does not mean that polymorphisms or mutations for the 
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GnRHR gene are definitively unassociated with the etiology of PCOS. Future studies 
should further investigate this relationship. 
These results are not without limitations. Firstly, the sample sizes of Cohen et al. 
(1999) and Li et al. (2011) were relatively small. With a disease as complex and 
heterogeneous as PCOS, large sample sizes are needed for clear consensus. Secondly, the 
different ethnicities under investigation limit the generalizability of the individual studies. 
The wide variability in the genome across ethnicities, even among healthy, non-diseased 
individuals, could prevent differentiation between pathologic variation and benign 
diversity. Thirdly, controls were matched for neither age nor BMI in these studies. Both 
of these variables serve as possible sources of genetic variability alone (Aunan et al., 
2016; Xia et al., 2013), which makes them potential confounders for PCOS research if 
left unadjusted. 
There are no further studies on these mutations as they relate to the pathology of 
PCOS. Based on these studies alone it is difficult to state if any association is present. 
Since consistency is paramount to being able to attribute causality, further studies on the 
rs6185 and rs1038246 SNPs are needed in order to determine whether or not these 
specific mutations in the GnRHR gene contribute to PCOS phenotypes. Alternatively, it 
is possible that polymorphisms in the GnRHR gene are not significant contributing 
factors to PCOS. Discovery of the true relationship requires data from many future 
studies.
  
1
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Publication 
Year 
Study 
Type 
Study Size PCOS 
Diagnosis 
Criteria 
Control 
Criteria 
Participant Baseline-
Matched 
Characteristics Participant Ethnicity 
PCOS 
Cases 
Controls Age BMI 
Cohen et al. 1999 
candidate 
gene 
80 75 NIH healthy - - Caucasian* 
Valkenburg 
et al. 
2009 
candidate 
gene 
518 2,996 Rotterdam 
from 
Rotterdam 
study** 
  Dutch Caucasian 
Li et al. 2011 
candidate 
gene 
261 687 Rotterdam healthy   Han Chinese 
Table 1.1 Study parameters for genetic polymorphisms of the GnRHR 
* Participant ethnicity was not specified, but subjects were recruited from Chicago, IL, USA 
** The Rotterdam Study is a prospective cohort study on chronic disease determinants comprised of Caucasian adults aged ≥55 
 
 
Studied Mutation(s) 
Mutation Type 
Mutation 
Location 
Possible 
Alleles 
Possible 
Genotypes 
Distribution 
Differences 
SNP DNA AA Allele Genotype 
Cohen et al. any insertion/deletion - - - - - 
Valkenburg et al. rs6185  W16S SNP exon 1 
Trp16,+ 
Ser16 
Trp/Trp 
  Trp/Ser 
Ser/Ser 
Li et al. rs1038246  [in 3’-UTR] SNP 3’-UTR 
G+ 
T 
GG 
  GT 
TT 
Table 1.2 Analyzed mutations and findings for studies on genetic polymorphisms of the GnRHR 
+ Indicates wild-type allele 
  
  
1
4 
Mutation Allele Study 
Phenotype Associations 
FSH LH Estrogen Testosterone FAI TSH Insulin Follicle Count Hyperandrogenism PCO 
rs6185 Ser16 Valkenburg et al. - - - ↓ ↓ - ↓ ↓ - - 
rs1038426 G Li et al. - - - - - ↑ ↑ - - - 
Table 1.3 Associations between genotypes of polymorphisms of the GnRHR and phenotype among PCOS cases 
↑ represents a positive correlation 
↓ represents a negative correlation 
 
FSH = follicle-stimulating hormone 
LH = luteinizing hormone 
FAI = free androgen index 
TSH = thyroid-stimulating hormone 
BMI = body mass index 
PCO = polycystic ovaries
 15 
 
Luteinizing Hormone (LH) Receptor 
 Luteinizing hormone (LH) is a heterodimer composed of an α and β subunit. The 
α subunit is shared among all glycoprotein hormones—a group consisting of LH, hCG 
(human chorionic gonadotropin), FSH, and TSH—and is encoded by the CGA gene on 
the long arm of chromosome 6 (6q14.3). The unique β subunit of each of the glycoprotein 
hormones provides the distinct biological functionality. The LH β subunit is encoded on 
the long arm of chromosome 19 (19q13.33) and is immediately adjacent to the gene for β 
subunit of hCG. Biologically, the function of LH is to bind and elicit a response from the 
LH receptor (LHR). 
 The LHR is a GPCR encoded on the short arm of chromosome 2 (2p16.3). 
Notably, the LHR is also the receptor for hCG so the LHR is sometimes called the 
luteinizing hormone/choriogonadotropin receptor (LHCGR). Receptors for LH are 
mainly expressed in the ovaries, testes, and adipose tissue. More specifically, in the ovary 
they are expressed in theca, granulosa, and luteal cells (Strauss et al., 2014, p. 27). Upon 
binding of LH, the LHR acts via a molecular signaling pathway to produce and secrete 
testosterone, which is then converted to estrogen. It also stimulates progesterone 
secretion and triggers ovulation via the classic “LH surge” at the end of the follicular 
phase. 
 There have been many studies on polymorphisms of the LH receptor in PCOS 
patients, almost all of  which have occurred in the last decade. The parameters and results 
of these studies are provided in Tables 2.1, 2.2, and 2.3. There are five SNPs that have 
been subjected to repeated analysis: rs12470652 (Asn291Ser), rs2293275 (Ser312Asn), 
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rs4539842 (18insLQ), rs13405728, and rs61996318 (Gln190Lys). Other SNPs have been 
analyzed in isolation as well. 
 
Asn291Ser, Ser312Asn, and 18insLQ  
The Valkenburg et al. (2009) candidate gene study analyzed three SNPs of the LH 
receptor gene in PCOS patients: rs12470652, which corresponds to a replacement of 
asparagine with serine at position 291 in the receptor protein (Asn291Ser); rs2293275, 
which corresponds to a replacement of serine with asparagine at position 312 in the 
receptor protein (Ser312Asn); and rs4539842, which results in an insertion of leucine and 
glutamine at position 18 in the receptor protein (18insLQ). The Asn291Ser 
polymorphism was found to be out of Hardy-Weinberg equilibrium even after adjustment 
and recalculation, and was thus excluded from further analysis due to possible 
sequencing errors. For the remaining two SNPs, there were no statistically significant 
differences in allele or genotype distribution between cases and controls, but there was a 
general trend towards decreased odds of PCOS with the presence of the mutant allele for 
each SNP. There were several phenotypic relationships found among PCOS cases. The 
18insLQ allele of the rs4539842 SNP was associated with lower levels of estrogen 
(estradiol), and the Asn312 allele of the rs2293275 SNP was associated with higher levels 
of FSH. The latter association did not meet statistical significance after an adjustment for 
the total number of tested SNPs, but a subsequent haplotype analysis further supported 
the initial association (P = 0.02) (Valkenburg et al., 2009). 
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 Capalbo et al. (2012) analyzed the same three SNPs from the Valkenburg et al. 
(2009) candidate gene study. Contrary to the results of Valkenburg et al. (2009), Capalbo 
et al. (2012) found all three SNPs to be in Hardy-Weinberg equilibrium. Furthermore, a 
significant difference in genotype distribution was found for the rs2293275 
polymorphism only, with the Asn312 allele conferring twice the odds of PCOS compared 
to controls (OR = 2.04, P = 0.001). No phenotypic associations were found among PCOS 
cases. 
 Thathapudi et al. (2015) performed an analysis of the Ser312Asn (rs2293275) 
SNP and found a significant difference in distribution of genotype and alleles between 
PCOS cases and controls. The Ser312 allele was found to occur more often in PCOS cases 
compared to controls (P = 0.0026). Furthermore, significant positive relationships were 
found between the Ser312 allele and LH and insulin levels as well as BMI in PCOS 
patients (P < 0.0001). A subsequent analysis by Almawi et al. (2015), however, found no 
such associations, either in genotype or phenotype. 
 The most recent analysis of the rs2293275 and rs4539842 SNPs was performed 
by El-Shal et al. (2016). For Ser312Asn (rs2293275), the Asn312 allele was significantly 
more common in PCOS cases compared to controls (P < 0.001). There were also 
significant positive associations with LH, LH/FSH ratio, free androgen index, insulin, 
glucose, and cholesterol. There was no difference in genotype distribution for the 
18insLQ (rs4539842) polymorphism, but significant positive associations were found 
between the mutant allele and LH, free androgen index, and glucose, potentially meaning 
that this SNP has association with PCOS phenotype only. 
 18 
 
 
rs13405728 
 The results of the GWAS performed by Chen et al. (2011) identified an 
association between a new SNP (rs13405738) and PCOS. This SNP was located in an 
intronic region of the LHR and resulted in an A>G transition. Information on the base 
change position was not available. No phenotypic relationships were found among PCOS 
patients with this SNP. Shortly after, Lerchbaum et al. (2011) performed a candidate gene 
study on this same SNP. No significant difference in allele or genotype distribution 
between cases and controls was found, but the mutant allele was associated with higher 
insulin and fasting glucose among PCOS cases (both P < 0.05). Of the four other studies 
on this polymorphism--Cui et al. (2012), Eriksen et al. (2012), Zhao et al. (2012), and 
Almawai et al. (2015)—only Cui et al. (2012) found a difference in genotype and allele 
distribution between PCOS cases and controls (P < 0.05). 
 
Gln190Lys (rs61996318) 
 Both Liu et al. (2012) and Liaqat et al. (2015) investigated the relationship 
between PCOS and the Gln190Lys polymorphism. Only Liaqat et al. (2015) found a 
significant difference in genotype and allele distribution between PCOS cases and 
controls (P = 0.030). Neither study adjusted for BMI. 
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Other SNPs   
 Multiple other SNPs of the LHR have been studied in isolation. A new candidate 
SNP in the LH receptor was found by Liu et al. (2012) in the course of the study at 
position NT27762960, where there was a loss of an A nucleotide. The homozygous 
genotype for the new SNP appeared to be less frequent among PCOS cases (P = 0.02), 
but the extremely small sample size gives these data little reliability as only 2 PCOS 
cases and 5 controls were homozygous for the new SNP. No other significant differences 
in genotype were observed for the new SNP. Mutharasan et al. found three SNPs to be 
associated with PCOS in a GWAS study: rs7562215, rs10495960, and rs7562879. The 
rs7562215 SNP was found to confer almost half the odds of PCOS compared to controls 
after adjustment for age, BMI, and ethnicity (OR = 0.56, P = 0.0036), while the 
rs10495960 SNP conferred 1.36 times the odds of PCOS (P = 0.024). No phenotypic 
relationships were found for the analyzed SNPs. Liaqat et al. (2015) found the 
rs111834744 SNP to confer almost three times the odds of PCOS (OR = 2.73, P = 0.001). 
Almawi et al. analyzed the effects of four new SNPs in addition to rs2293275 and 
rs13405728. rs7371084 and rs4953616 were found to have significantly different 
distributions between cases and controls, with the rs7371084 SNP conferring 0.39 times 
the odds of PCOS (P = 0.001) and the rs4953616 SNP conferring 1.61 times the odds of 
PCOS (P = 0.001). No such association was found for rs4597581 and rs4073366. 
Furthermore, a significant association was found between rs7371084 and testosterone, 
free androgen index, and BMI (P < 0.05), and a negative association was found between 
rs4953616 and levels of testosterone and cholesterol (P < 0.05). 
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 The results of these studies are conflicting. Of the SNPs that have been 
investigated in multiple studies, there is much discrepancy. Six studies have been 
performed on the rs13405738 SNP, but only two—Chen et al. (2011) and Cui et al. 
(2012)—found an association between this SNP and PCOS. These two studies were both 
performed among Han Chinese populations, while other studies were performed among 
Caucasian and Arab populations. Both Chen et al. (2011) and Cui et al. (2012) adjusted 
the results for age and BMI, as did most others. It is possible that this association only 
exists in populations of Han Chinese origin, but this is a strong assertion with little 
evidence behind it. 
 There were four studies performed on the Ser312Asn polymorphism in 
Caucasian, Sardinian, South Indian, and Egyptian populations. All studies except for 
Valkenburg et al. (2009) found an association between this SNP and PCOS. It is possible 
that BMI altered these results, as Valkenburg et al. (2009) was the only study among 
these four to neither match nor correct for BMI as a potential confounding factor. There 
were three studies performed on the 18insLQ polymorphism—Valkenburg et al. (2009), 
Capalbo et al. (2012), and El-Shal et al. (2016). However, this time only Valkenburg et 
al. (2009) found an association between this SNP and PCOS. Only two studies—
Valkenburg et al. (2009) and Capalbo et al. (2012)—examined the Asn291Ser 
polymorphism and neither found an association. For the Gln190Lys polymorphism, only 
one of the two studies found an association. However, neither of these studies matched or 
adjusted for BMI. All remaining studied SNPs were unique in their analysis. It is unsure 
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as to whether or not a true association exists for any, as repeated studies are needed to 
begin to assess this. 
 The results show very little evidence for phenotypic relationship with the studied 
SNPs. Very few studies found phenotypic associations and the results of these are not at 
all aligned with each other. Only five SNPs have supposed phenotypic associations: 
rs13405728, rs2293275, rs4539842, rs7371084, and rs4953616. It is too early to tell 
whether true associations exist or not. 
 The limitations of these studies are numerous, similar to the limitations found in 
the GnRHR studies. First and foremost, most studies are limited by sample size. This 
significantly limits the ability to detect the true relationships between these SNPs and 
PCOS, especially among participants homozygous for the mutant allele as this generally 
includes only a handful of participants. Second, almost all studies rely on the Rotterdam 
criteria as a method of diagnosis of PCOS. While this serves to increase sample size, it 
decreases the homogeneity of the study population and thus makes it difficult to compare 
“normal” and “abnormal” genotypes. Third, there is much variety in the ethnicities of 
participants across studies, which, as mentioned in the discussion of the GnRHR, is a 
potential confounding variable. Furthermore, matching and adjusting for age and BMI is 
inconsistent across studies. As previously mentioned, these are also potential 
confounding variables. Many more studies on these polymorphisms are necessary in 
order to be certain of their associations due to the conflicting results of existing research.
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Publication 
Year 
Study 
Type 
Study Size PCOS 
Diagnosis 
Criteria 
Control 
Criteria 
Participant Baseline-
Matched Characteristics Participant 
Ethnicity PCOS 
Cases 
Controls Age BMI 
Valkenburg 
et al. 
2009 
candidate 
gene 
518 2,996 Rotterdam 
from Rotterdam 
study* 
  Dutch Caucasian 
Chen et al. 2011 GWAS 3,338** 5,792* Rotterdam healthy   Han Chinese 
Lerchbaum 
et al. 
2011 
candidate 
gene 
545 317 Rotterdam healthy   Caucasian 
Capalbo et 
al. 
2012 
candidate 
gene 
198 187 Rotterdam healthy   Sardinian 
Cui et al. 2012 
candidate 
gene 
1,731 4,964 Rotterdam healthy   Han Chinese 
Eriksen et al. 2012 
candidate 
gene 
169 248 Rotterdam healthy   
Danish 
Caucasian 
Liu et al. 2012 
candidate 
gene 
315 212 Rotterdam healthy   Han Chinese 
Mutharasan 
et al. 
2012 
candidate 
gene 
905 956 NIH healthy   
European 
Caucasian 
Zhao et al. 2012 
family-
based 
analysis 
828*** - Rotterdam - - - Han Chinese 
Liaqat et al. 2015 
candidate 
gene 
96 96 Rotterdam healthy   Pakistani 
Thathapudi 
et al. 
2015 
candidate 
gene 
204 204 AES healthy   South Indian 
Almawi et 
al. 
2015 
candidate 
gene 
203 211 Rotterdam healthy   Bahraini Arab 
El-Shal et al. 2016 
candidate 
gene 
210 200 Rotterdam healthy   Egyptian 
Table 2.1 Study parameters for genetic polymorphisms of the LHR 
* The Rotterdam Study is a prospective cohort study on chronic disease determinants comprised of Caucasian adults aged ≥55 
** Total participants from Replication 1 and Replication 2 
*** The study was comprised of 276 family trios (mother, father, PCOS offspring)  
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Mutation Type Site DNA Change 
Protein 
Change 
Possible 
Alleles 
Possible 
Genotypes 
Published 
Studies 
Controlled 
Variables 
Distribution 
Differences 
Age BMI Allele Genotype 
rs12470652 SNP exon 10 872 A>G Asn291Ser 
Asn291,+ 
Ser291 
Asn/Asn 
Asn/Ser 
Ser/Ser 
Valkenburg 
et al. 
    
Capalbo et 
al. 
    
rs2293275 SNP exon 10 935 G>A Ser312Asn 
Ser312,+ 
Asn312 
Ser/Ser 
Ser/Asn 
Asn/Asn 
Valkenburg 
et al. 
    
Capalbo et 
al. 
    
Thathapudi 
et al. 
    
Almawi et 
al. 
    
El-Shal et al.     
rs4539842 insertion exon 1 54insCTCCAG 18insLQ 
nonLQ18,+ 
insLQ18 
non/non 
non/ins 
ins/ins 
Valkenburg 
et al. 
    
Capalbo et 
al. 
    
El-Shal et al.     
rs13405728 SNP intron 
position 
unknown 
- 
A+ 
G 
AA 
AG 
GG 
Chen et al.     
Lerchbaum 
et al. 
    
Cui et al.     
Eriksen et 
al. 
    
Zhao et al.     
Almawi et 
al. 
    
rs61996318 SNP exon 568 C>A Gln190Lys 
C+ 
A 
CC 
CA 
AA 
Liu et al.     
Liaqat et al.     
Table 2.2 Analyzed mutations and findings for studies on genetic polymorphisms of the LHR (+ Indicates wild-type allele) 
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rs7562215 SNP - - - 
G+ 
T 
GG 
GT 
TT 
Mutharasan 
et al. 
    
rs10495960 SNP intron 1 - - 
A+ 
G 
AA 
AG 
GG 
Mutharasan 
et al. 
    
rs7562879 SNP - - - - - 
Mutharasan 
et al. 
    
rs11183474
4 
deletion intron - - 
A+ 
del 
AA 
A/del 
del/del 
Liaqat et al.     
rs7371084 SNP intron - - 
T+ 
C 
TT 
TC 
CC 
Almawi et 
al. 
    
rs4953616 SNP - - - 
T+ 
C 
TT 
TC 
CC 
Almawi et 
al. 
    
rs4597581 SNP - - - 
A+ 
G 
AA 
AG 
GG 
Almawi et 
al. 
    
rs4073366 SNP intron 1 - - 
G+ 
C 
GG 
GC 
CC 
Almawi et 
al. 
    
N/A deletion exon 7 - - 
A+ 
del 
AA 
A/del 
del/del 
Liu et al.     
Table 2.2 (Continued) 
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Phenotypic 
Characteristics 
rs13405728 rs2293275 rs4539842 rs7371084 rs4953616 
A G Ser312 Asn312 non ins T C T C 
Endocrine  
FSH    ↑2       
LH   ↑3 ↑4  ↑4     
LH/FSH ratio    ↑4       
Estrogen      ↓2     
Testosterone        ↓5  ↓5 
FAI    ↑4  ↑4  ↓5   
Hyperandrogenism           
TSH           
Metabolic  
Insulin  ↑1 ↑3 ↑4       
Glucose  ↑1  ↑4  ↑4     
Cholesterol    ↑4      ↓5 
Clinical  
BMI   ↑3     ↑5   
PCO           
Follicle Count           
Table 2.3 Associations between genotypes of polymorphisms of the LHR and phenotype among PCOS cases 
↑ represents a positive correlation 
↓ represents a negative correlation 
 
1 Lerchbaum et al. 
2 Valkenburg et al. 
3 Thathapudi et al. 
4 El-Shal et al. 
5 Almawi et al. 
 
FAI = free androgen index 
TSH = thyroid-stimulating hormone 
SHBG = sex hormone-binding globulin 
BMI = body mass index
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Follicle-Stimulating Hormone (FSH) Receptor 
 Similar to LH, FSH is a heterodimer composed of an α and β subunit. The FSH β 
subunit is encoded on the short arm of chromosome 11 (11p14.1). Biologically, the 
function of FSH is to bind and elicit a response from the FSH receptor (FSHR). The 
FSHR is a GPCR encoded on the short arm of chromosome 2 (2p16.3), which is the same 
locus as the LHR. The FSHR is mainly expressed in the ovaries and testes. Specifically, 
the FSHR is expressed within the granulosa cells of the ovary. Upon binding FSH, the 
FSHR acts through a molecular signaling pathway to aid in testosterone synthesis and 
secretion as well as folliculogenesis. 
 There have been many studies on polymorphisms of the FSHR, primarily because 
it has been identified as a key susceptibility locus in many GWAS (Mutharasan et al., 
2012; Zhao et al., 2015). The parameters and results of these studies are provided below 
in Tables 3.1, 3.2, and 3.3. There are five SNPs that have been subjected to repeated 
analysis: rs6165, rs6166, rs2268361, rs2349415, and rs121909658. Eleven other SNPs 
have been studied, but they have all been analyzed in isolation. 
 
Thr307Ala (rs6165) and Asn680Ser (rs6166) 
 There have been twelve analyses of rs6165 and rs6166. Both of these SNPs are 
located in exon 10 and correspond to an A to G transition. The rs6165 SNP is located at 
position 919 and results in an amino acid change from threonine to alanine at position 
307 of the receptor protein. The rs6166 SNP is located at position 2039 and results in an 
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amino acid change from asparagine to serine at position 680 of the receptor protein. Most 
studies performed an analysis of linkage disequilibrium and found near-complete linkage 
disequilibrium with D’ values close to 1.0 for each study. This indicates that there is very 
little recombination of these SNPs, which means that they are almost always inherited 
together. Analysis of rs6165 found no significant distribution differences between cases 
and controls in any of the studies. In the analysis of rs6166, only three studies found a 
difference in genotype distribution between PCOS cases and controls—Gu et al. (2010), 
Dolfin et al. (2011), and Mutharasan et al. (2012). 
Several phenotypic relationships were found among PCOS cases for each SNP, 
however. For rs6165, the wild-type allele (Thr307) was associated with higher levels of 
FSH and LH (Singhasena et al., 2014), and the mutant allele (Ala307) was associated with 
higher levels of FSH (Wu et al., 2014). The discrepancy on the effect of this 
polymorphism on FSH levels is of interest, but definitively unexplainable. Singhasena et 
al. (2014) performed their analysis among participants of Thai ethnicity while 
participants of Wu et al. were of Han Chinese ethnicity. Therefore, it is possible that 
ethnicity is a factor in this genotype-phenotype relationship. Both studies either matched 
or controlled for BMI, so it is unlikely that this is skewing the true relationship. Also, the 
study sizes were slightly different—Wu et al. had 215 PCOS cases while Singhasena et 
al. (2014) only had 133. It is possible that this affected the association between genotype 
and FSH levels, but this is merely speculation.  
For rs6166, the mutant allele (Ser680) was found to be associated with higher 
levels of both FSH and LH among PCOS cases. These associations had double-
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confirmation—the positive association between Ser680 and FSH was found by 
Valkenburg et al. (2009) and Wu et al. (2014), while the positive association between 
Ser680 and LH was found by Singhasena et al. (2014) and Valkenburg et al. (2009). 
However, Singhasena et al. (2014) found this relationship to exist among heterozygotes 
only. A positive association between the mutant allele and presence of hyperandrogenism 
was found by Valkenburg et al. (2009), and Wu et al. (2014) found a negative association 
between the mutant allele and prolactin levels among heterozygotes alone. Based on 
these results, it is possible that a true association exists between this SNP and levels of 
FSH and LH but further research is needed to be certain. 
 
rs2349415 and rs2268361 
 There have been three studies each of rs2349415 and rs2268361: Shi et al. (2012), 
Du et al. (2015), and Zhao et al. (2015). However, Du et al. (2015) examined these two 
polymorphisms for association with PCO morphology and not PCOS itself. Shi et al. 
(2012) found an association between both of these SNPs and PCOS, while Zhao et al. 
(2015) only found an association between rs2349415 and PCOS. Du et al. (2015) found 
that patients with the G/A genotype for the rs2268361 polymorphism were significantly 
more likely to exhibit PCO (P = 0.03), but no significant associations were found for the 
rs2349415 polymorphism. Analysis of the relationship between the two polymorphisms 
and serum hormone levels revealed that the rs2268361 polymorphism was significantly 
associated with levels of FSH, estrogen, and SHBG among patients with PCO, but no 
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such relationship was found for non-PCO patients. Analysis of the rs2349415 
polymorphism showed an association for only SHBG among PCO patients. No 
phenotypic relationships were found by Shi et al. (2012) or Zhao et al. (2015). 
 
Ala189Val (rs121909658) 
 Only Takakura et al. (2001) and Tong et al. (2001) have been investigated the 
relationship between rs121909658 and PCOS. This SNP is located within exon 7 of the 
receptor gene and corresponds to a C>T transition at position 566 (566 C>T). This results 
in an amino acid change from alanine to valine at position 189 of the receptor protein. 
Takakura et al. (2001) performed the analysis among Japanese participants, while Tong et 
al. (2001) studied Chinese Singaporean participants. Neither study matched or adjusted 
for age or BMI, and neither study found an association between this SNP and PCOS. 
Furthermore, no relationships between phenotype and genotype were found. The study 
performed by Takakura et al. (2001) was very small—only 38 cases and 3 controls were 
used. The sample sizes used by Tong et al. (2001), although larger than Takakura et al. 
(2001), are still relatively small (124 cases). It is difficult to tell whether a larger study 
that controls for age and BMI would be able to find an association or not. 
 The limitations that plague these results are the same as in previous analyses. 
Small sample sizes are a continuous problem, as is heterogeneous study populations 
resulting from using the Rotterdam criteria as a method of PCOS diagnosis. The wide 
variability in participant ethnicity is also a cause of inconsistency and uncertainty. 
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Furthermore, less than half of the studies adjusted for age and BMI, which are possible 
confounders as previously mentioned. Repeated studies of proper construct are needed to 
assess the true associations between these SNPs and PCOS.   
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Publication 
Year 
Study 
Type 
Study Size PCOS 
Diagnosis 
Criteria 
Control 
Criteria 
Participant Baseline-
Matched 
Characteristics Participant Ethnicity 
PCOS 
Cases 
Controls Age BMI 
Takakura et 
al. 
2001 
candidate 
gene 
38 3 Rotterdam* healthy   Japanese 
Tong et al. 2001 
candidate 
gene 
124 236 Rotterdam** healthy   Chinese Singapore 
Unsal et al. 2009 
candidate 
gene 
44 50 Rotterdam healthy   Turkish Caucasian 
Valkenburg 
et al. 
2009 
candidate 
gene 
518 2,996 Rotterdam 
from 
Rotterdam 
study*** 
  Dutch Caucasian 
Gu et al. 2010 
candidate 
gene 
235 128 Rotterdam healthy   Korean 
Du et al. 2010 
candidate 
gene 
60 92 Rotterdam healthy   Han Chinese 
Dolfin et al. 2011 
candidate 
gene 
40 66 NIH‡ healthy   Italian 
Shi et al. 2012 GWAS 1,510 2,106 Rotterdam healthy   Han Chinese 
Mutharasan 
et al. 
2012 
candidate 
gene 
905 956 NIH healthy   European Caucasian 
Fu et al. 2013 
candidate 
gene 
384 768 Rotterdam healthy   Han Chinese 
Singhasena et 
al. 
2014 
candidate 
gene 
133 132 Rotterdam healthy   Thai 
Wu et al. 2014 
candidate 
gene 
215 205 Rotterdam healthy   Han Chinese 
Czeczuga-
Semeniuk et 
al. 
2014 
candidate 
gene 
294 78 Rotterdam healthy   Polish Caucasian 
Liaqat et al. 2015 
candidate 
gene 
96 96 Rotterdam healthy   Pakistani 
Table 3.1 Study parameters for genetic polymorphisms of the FSHR 
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Almawi et al. 2015 
candidate 
gene 
203 211 Rotterdam healthy   Bahraini Arab 
Du et al. 2015 
candidate 
gene 
384 63 
Rotterdam, 
PCO 
PCOS, non-
PCO 
  Han Chinese 
Zhao et al. 2015 
family-
based 
analysis 
963‡‡ - Rotterdam - - - Han Chinese 
Table 3.1 Continued 
* The investigators used the criteria of the Japan Society of Obstetrics and Gynecology, which most resembles the Rotterdam criteria with the addition 
of high LH and LH/FSH ratio as a requirement 
** The diagnosis criteria required: 1) anovulatory hyperandrogenism; 2) elevated LH/FSH ratio; and 3) PCO morphology. These criteria are closest to 
the Rotterdam criteria. 
*** The Rotterdam Study is a prospective cohort study on chronic disease determinants comprised of Caucasian adults aged ≥55 
‡ The criteria used to diagnose PCOS most closely resembled the NIH criteria, but required the NIH criteria with the addition of PCO morphology 
‡‡ The study was comprised of 321 family trios (mother, father, PCOS offspring) 
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Mutation 
Mutation 
Type 
Site 
DNA 
Change 
Protein 
Change 
Possible 
Alleles 
Possible 
Genotypes 
Published Studies 
Controlled 
Variables 
Distribution 
Differences 
Age BMI Allele 
Genoty
pe 
rs6165 SNP exon 10 919 A>G Thr307Ala 
A+ 
G 
AA 
AG 
GG 
Tong et al.     
Unsal et al.     
Valkenburg et al.     
Gu et al.     
Du et al.     
Dolfin et al.     
Mutharasan et al.     
Fu et al.     
Singhasena et al.     
Wu et al.     
Czeczuga-Semeniuk 
et al. 
    
Liaqat et al.     
rs6166 SNP exon 10 2039 A>G Asn680Ser 
A+ 
G 
AA 
AG 
GG 
Tong et al.     
Unsal et al.     
Valkenburg et al.     
Gu et al.     
Du et al.     
Fu et al.     
Singhasena et al.     
Wu et al.     
Czeczuga-Semeniuk 
et al. 
    
Liaqat et al.     
rs2349415 SNP intron 533 T>C [intronic] 
T+ 
C 
TT 
TC 
CC 
Shi et al.     
Du et al.   - - 
Zhao et al.     
rs2268361 SNP intron 8 - [intronic] 
G+ 
A 
GG 
GA 
AA 
Shi et al.     
Du et al.   - - 
Zhao et al.     
Table 3.2 Analyzed mutations and findings for studies on genetic polymorphisms of the FSHR (+ Indicates wild-type allele) 
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rs121909658 SNP exon 7 566 C>T Ala189Val 
C+ 
T 
CC 
CT 
TT 
Takakura et al.     
Tong et al.     
rs121909659 SNP exon 6 479 T>C Ile160Thr 
T+ 
C 
TT 
TC 
CC 
Takakura et al.     
rs386833515 SNP exon 9 671 A>T Asp224Val 
A+ 
T 
AA 
AT 
TT 
Takakura et al.     
rs121909660 SNP exon 10 1717 C>T Arg573Cys 
C+ 
T 
CC 
CT 
TT 
Takakura et al.     
rs386833513 SNP exon 10 1801 C>G Leu601Val 
C+ 
G 
CC 
CG 
GG 
Takakura et al.     
rs10865238 SNP - - - 
A+ 
G 
AA 
AG 
GG 
Shi et al.     
rs1922476 SNP - - - - - Mutharasan et al.     
rs46166 SNP - - - 
G+ 
A 
GG 
GA 
AA 
Almawi et al.     
rs1007541 SNP intron - [intronic] 
G+ 
A 
GG 
GA 
AA 
Almawi et al.     
rs11692782 SNP - - - 
A+ 
T 
AA 
AT 
TT 
Almawi et al.     
rs2055571 SNP - - - 
G+ 
A 
GG 
GA 
AA 
Almawi et al.     
rs1394205 SNP 5’-UTR -29 G>A [5’-UTR] 
G+ 
A 
GG 
GA 
AA 
Almawi et al.     
Table 3.2 (Continued)  
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Phenotypic Characteristics 
rs6165 rs6166 rs2268361 rs2349415 
A G A G G A C T 
Endocrine  
FSH ↑1 ↑3  ↑2, 3 ↑4    
LH ↑1   ↑1*,2     
LH/FSH ratio         
Estrogen     ↓4    
Testosterone         
FAI         
Hyperandrogenism    ↑2     
TSH         
Prolactin    ↓*3     
SHBG     ↑4  ↓4  
Metabolic  
Insulin         
Glucose         
Cholesterol         
Clinical  
BMI         
PCO     ↑*4    
Follicle Count         
Table 3.3 Associations between genotypes of polymorphisms of the FSHR and phenotype among PCOS cases 
↑ represents a positive correlation 
↓ represents a negative correlation 
* This association was only found among heterozygotes 
1 Singhasena et al. 
2 Valkenburg et al. 
3 Wu et al. 
4 Du et al. 
 
FAI = free androgen index 
TSH = thyroid-stimulating hormone 
SHBG = sex hormone-binding globulin 
BMI = body mass index 
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Anti-Müllerian Hormone (AMH) Receptor 
 Anti-Müllerian Hormone (AMH) is a member of the TGFβ family and is encoded 
by the short arm of chromosome 19 (19p13.3). AMH is most commonly known for its 
function in causing atrophy of the Müllerian ducts during embryogenesis, but it has 
several important roles in female reproduction as well. It is involved in folliculogenesis 
and expressed by the granulosa cells of developing follicles. Its levels have also been 
shown to correlate with the number of remaining antral follicles, so it is thus a good 
marker of ovarian reserve (Tremellen et al., 2015; Xu et al., 2017). The receptor for 
AMH (AMHR2) is expressed on the long arm of chromosome 12 (12q13.13). Despite its 
classical role in regression of the Müllerian ducts, it is also expressed in large quantities 
in the ovary. Additionally, some research has recently shown that AMH receptors are 
also expressed in the brain and may be involved in initiation of GnRH release from 
hypothalamic neurons (Cimino et al., 2016). 
 There have only been a handful of studies on the relationship between 
polymorphisms of the AMHR2 gene and PCOS, the parameters and results of which are 
provided in Tables 4.1, 4.2, and 4.3. However, most have analyzed the same 
polymorphism: rs2002555. This SNP is located within the 3’-untranslated region (UTR) 
and results in an A to G transition at position 482 (-482 A>G). The only group to find a 
statistically significant relationship was Georgopoulos et al. (2013), who found that the 
A>G polymorphism occurred over 50% more often in PCOS cases compared to controls 
(odds ratio, 1.64 ± 0.15; P = 0.001). Furthermore, this relationship was unchanged when 
the analysis was restricted to PCOS cases diagnosed via the NIH criteria (odds ratio, 1.66 
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± 0.15; P < 0.001). Among PCOS cases, the GG genotype was associated with lower LH 
levels, a lower LH/FSH ratio, and lower prolactin levels (P = 0.003, P = 0.010, and P = 
0.004, respectively). No other studies found phenotypic relationships among PCOS cases. 
Other studied polymorphisms included rs2272002 and general polymorphic differences, 
but neither found associations with PCOS. 
 Because AMH in involved in follicular development and has been shown to be an 
indicator of the number of remaining antral follicles in women, it is somewhat unlikely 
that polymorphisms of the AMHR2 play an etiologic role in PCOS based on the current 
knowledge of AMH. However, it has been shown that polymorphisms of the AMHR2 are 
involved in infertility (Yoshida et al., 2014) as well as natural menopause age (Braem et 
al., 2013), and that expression of the AMHR2 is increased in women with endometriosis 
(Carrarelli et al., 2014). Therefore, it is possible that polymorphisms of the AMHR2 play 
an important role in pathological progression rather than in initial causation. 
 These studies have limitations much the same as the limitations of the other 
analyzed receptors. With the exception of maybe Georgopoulos et al. (2014), the sample 
sizes are all quite small, which may limit the power of the studies to analyze the true 
associations of the selected SNPs. All studies also relied on the Rotterdam criteria for 
diagnosis of PCOS, which, as previously mentioned, creates a heterogeneous case 
population. Finally, none of the studies matched or corrected for BMI as a potential 
confounder and only a few matched for age. It is possible that these characteristics are 
important in baseline genetic variability among study participants.
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Publication 
Year 
Study 
Type 
Study Size PCOS 
Diagnosis 
Criteria 
Control 
Criteria 
Participant Baseline-
Matched 
Characteristics Participant Ethnicity 
PCOS 
Cases 
Controls Age BMI 
Wang et al. 2002 
candidate 
gene 
43 20 Rotterdam* healthy   Japanese 
Kevenaar et 
al. 
2008 
candidate 
gene 
331 3,667 Rotterdam healthy   Dutch Caucasian 
Georgopoulos 
et al. 
2013 
candidate 
gene 
858 309 Rotterdam healthy   Greek Caucasian 
Czeczuga-
Semeniuk et 
al. 
2014 
candidate 
gene 
294 78 Rotterdam healthy   Polish Caucasian 
Zheng et al. 2016 
candidate 
gene 
141 123 Rotterdam healthy   Chinese 
Table 4.1 Study parameters for genetic polymorphisms of the AMHRII 
* The investigators used the criteria of the Japan Society of Obstetrics and Gynecology, which most resembles the Rotterdam criteria with the addition 
of high LH and LH/FSH ratio as a requirement 
 
Mutation 
Mutation 
Type 
Location 
DNA 
Change 
Protein 
Change 
Possible 
Alleles 
Possible 
Genotypes 
Published Studies 
Controlled 
Variables 
Distribution 
Differences 
Age BMI Allele Genotype 
rs2002555 SNP 5’-UTR -482 A>G [5’-UTR] 
A+ 
G 
AA 
AG 
GG 
Kevenaar et al.     
Georgopoulos et al.     
Czeczuga-Semeniuk 
et al. 
    
rs2272002 SNP intron - [intronic] 
A+ 
T 
AA 
AT 
TT 
Zheng et al.     
any any - - - - - al.     
Table 4.2 Analyzed mutations and findings for studies on genetic polymorphisms of the AMHRII (+ Indicates wild-type allele)  
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Phenotypic Characteristics 
rs2002555 
A G 
Endocrine 
FSH   
LH  ↓1 
LH/FSH ratio  ↓1 
Estrogen   
Testosterone   
FAI   
Hyperandrogenism   
TSH   
Prolactin  ↓1 
SHBG   
Metabolic 
Insulin   
Glucose   
Cholesterol   
Clinical 
BMI   
PCO   
Follicle Count   
Table 4.3 Associations between genotypes of polymorphisms of the AMHRII and phenotype among PCOS cases 
↑ represents a positive correlation 
↓ represents a negative correlation 
1 Georgopoulos et al. 
 
FSH = follicle-stimulating hormone 
LH = luteinizing hormone 
FAI = free androgen index 
TSH = thyroid-stimulating hormone 
SHBG = sex hormone-binding globulin 
BMI = body mass index 
PCO = polycystic ovaries
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Estrogen Receptor 
 Both estrogen and progesterone are steroid hormones. Their molecular structure is 
derived from cholesterol, which is based on a four-ring molecule. Estrogen is created in 
vivo via aromatase-catalyzed conversion of testosterone, which is synthesized and 
secreted from the ovary. Estrogen is unique among the steroid hormones in that there are 
actually two different receptors encoded by two different genes: ER-α (ESR1) and ER-β 
(ESR2), encoded by 6q25.1-2 and 14q23.2-3, respectively. They are expressed in 
different ratios in different bodily tissues and ultimately lead to production of a wide 
variety of gene products. Since estrogen is a steroid hormone, its receptor is located in the 
nucleus rather than on the cell surface. Because of this, its actions are generally 
associated with formation of homodimers that alter transcription of target DNA 
sequences to either increase or decrease production of the desired gene product (Strauss, 
2014, p. 104). 
There were three available studies on polymorphisms of the estrogen receptor as 
they relate to PCOS. Specific parameters and results of each study are provided in Tables 
5.1, 5.2, and 5.3. Specific parameters and findings for each study are provided below. In 
2010, Kim et al. (2010) investigated the relationship between the rs4986938 SNP, which 
represents a G>A point mutation at position 1730 in the 3’-UTR (+1730 G>A) of the 
estrogen receptor-β gene (ER-β, ESR2), among a population of Korean women. 
Significant differences were found for both allele and genotype distribution between 
cases and controls (P = 0.009, P = 0.003, respectively). No significant relationships were 
found between phenotype and genotype among PCOS cases. 
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Silva et al. (2015) analyzed the relationship between PCOS and two SNPs within 
intron 1 of the estrogen receptor-α gene (ER-α, ESR1): rs2234693 and rs9340799. The 
rs2234693 SNP corresponds to a T/C transition at position 397, and the rs9340799 SNP 
corresponds to an A/G transition at position 351. There were no significant differences 
found in genotype or allele frequencies between cases and controls for either SNP. The C 
allele of the rs2234693 correlated positively with levels of C-reactive protein (CRP) 
among PCOS cases (P = 0.025), while the T allele correlated slightly with testosterone 
levels (P = 0.051, r = 0.199). The G allele of the rs9340799 SNP correlated positively 
with fasting glucose levels (P = 0.029) and testosterone levels (P <0.0001, r = 0.575) 
among PCOS cases. 
Finally, Liaqat et al. (2015) analyzed three polymorphisms of the ESR1 gene 
(rs2234693, rs9340799, and rs8179176) and one polymorphism of the ESR2 gene 
(rs4986938). All SNPs were located within intronic regions of the gene. Statistically 
significant differences in genotype and allele distribution were found between cases and 
controls for all SNPs, and all were found to confer and increased odds of PCOS (OR = 
1.84, P = 0.005; OR = 1.68, P = 0.010; OR = 2.97, P = 0.006; and OR = 1.87, P = 0.005, 
respectively). 
Similar to the GnRH receptor gene, too few studies exist on polymorphisms of the 
estrogen receptor genes as they relate to PCOS etiology and pathology. Based on these 
studies alone, it is hard to discern any type of true association. Kim et al. (2010) found an 
association between genotype and allele frequencies and PCOS in the ESR2 gene, but the 
results were not adjusted for age or BMI. Liaqat et al. (2015), however, further confirmed 
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this association. Silva et al. (2015) found no genotype or allele associations for 
polymorphisms of the ESR1 gene but several phenotypic relationships were presented 
among PCOS cases. Conversely, Liaqat et al. (2015) found associations between PCOS 
and all three SNPs of the ESR1 gene. Limitations for this set of studies include small 
sample sizes, the lack of generalizability due to ethnicity, lack of matching and correcting 
for confounders such as age and BMI, and simple lack of repeated studies.
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Publication 
Year 
Study 
Type 
Study Size PCOS 
Diagnosis 
Criteria 
Control 
Criteria 
Participant Baseline-
Matched 
Characteristics Participant Ethnicity 
PCOS 
Cases 
Controls Age BMI 
Kim et al. 2010 
candidate 
gene 
138 290 Rotterdam 
188 infertile* 
102 healthy 
  Korean 
Silva et al. 2015 
candidate 
gene 
99 104 Rotterdam healthy   Brazilian 
Liaqat et al. 2015 
candidate  
gene 
96 96 Rotterdam healthy   Pakistani 
Table 5.1 Study parameters for genetic polymorphisms of the ER 
* Infertility was due to uterine, tubal, or male factors and not due to other pathologies 
Mutation 
Mutation 
Type 
Location 
DNA 
Change 
Protein 
Change 
Possible 
Alleles 
Possible 
Genotypes 
Published 
Studies 
Statistical 
Adjustment 
Distribution 
Differences 
Age BMI Allele Genotype 
rs9340799 SNP 
intron 1 of 
ER-α 
gene 
351 A>G [intronic] 
A+ 
G 
AA 
AG 
GG 
Silva et al.     
Liaqat et al.     
rs2234693 SNP 
intron 1 of 
ER-α 
gene 
397 T>C [intronic] 
T+ 
C 
TT 
TC 
CC 
Silva et al.     
Liaqat et al.     
rs8179176 SNP 
intron 1 of 
ER-α 
gene 
398 C>T [intronic] 
C+ 
T 
CC 
CT 
TT 
Liaqat et al.     
rs4986938 SNP 
3’-UTR 
of ER-β 
gene 
+1730 G>A [3’-UTR] 
G+ 
A 
GG 
GA 
AA 
Kim et al.     
Liaqat et al.     
Table 5.2 Analyzed mutations and findings for studies on genetic polymorphisms of the ER (+ Indicates wild-type allele) 
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Mutation Allele Study 
Phenotype Associations 
FSH LH E T FAI TSH Ins CRP G Follicle Count HA PCO 
rs2234693 
C 
Silva et al. 
- - - - - - - ↑ - - - - 
T - - - ↑ - - - - - - - - 
rs9340799 G Silva et al. - - - ↑ - - - - ↑ - - - 
Table 5.3 Associations between genotypes of polymorphisms of the ER and phenotype among PCOS cases 
↑ represents a positive correlation 
↓ represents a negative correlation 
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Progesterone Receptor 
 Progesterone, along with estrogen, is a steroid hormone with a nuclear receptor. 
Progesterone is synthesized via 3β-hydroxysteroid dehydrogenase-catalyzed conversion 
of pregnenolone (Strauss, 2014, p. 70). Its receptor is encoded by the long arm of 
chromosome 11 (11q22.1) and has two promoter regions in the first exon and thus two 
transcriptional start sites, which leads to two different receptor isoforms. Nearly 100% of 
progesterone receptor (PR) expression in females is in the endometrium, as progesterone 
is mainly involved in maintenance of pregnancy. As with estrogen, the PR is found 
within the nucleus and acts via homodimer formation bind and alter transcription of 
target DNA segments (Strauss, 2014, p. 104). 
Karadeniz et al. (2007) performed the only study to date on polymorphisms of the 
progesterone receptor as they relate to PCOS. Details on the parameters and findings are 
provided below. The item of study was a polymorphism known as PROGINS, which is a 
306-bp insertion mutation discovered in 1995 in the intron region of DNA between exons 
7 and 8. This segment of DNA encodes the hormone-binding domain of the progesterone 
receptor (Rowe, 1995). Genetic analysis revealed two alleles: T1 (wild-type) and T2 
(mutant). No significant differences in genotype or allele distribution were found between 
cases and controls. Among PCOS cases, a statistically significant relationship was found 
between allele and FSH levels, with the presence of the T2 allele corresponding to lower 
levels of FSH compared to cases homozygous for the T1 allele (P = 0.04) (Karadeniz et 
al., 2007). 
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Since this is the only available study on polymorphisms in the progesterone 
receptor gene in PCOS patients, little can be said about its true association with the 
pathology. However, since the main role of progesterone is to maintain pregnancy, it is 
unlikely that polymorphisms of the receptor are associated with PCOS.
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Publication 
Year 
Study 
Type 
Study Size PCOS 
Diagnosis 
Criteria 
Control 
Criteria 
Participant Baseline-
Matched 
Characteristics Participant Ethnicity 
PCOS 
Cases 
Controls Age BMI 
Karadeniz 
et al. 
2007 
candidate 
gene 
95 99 Rotterdam healthy   Turkish* 
Table 6.1 Study parameters for genetic polymorphisms of the PR 
* Participant ethnicity was not explicitly disclosed, but the study was conducted in Izmir, Turkey 
 
Studied Mutation(s) 
Mutation Type 
Mutation 
Location 
Possible 
Alleles 
Possible 
Genotypes 
Distribution 
Differences 
db SNP DNA AA Allele Genotype 
Karadeniz et al. PROGINS insertion 
intron between 
exons 7 and 8 
T1+ 
T2 
T1/T1 
  T1/T2 
T2/T2 
Table 6.2 Analyzed mutations and findings for studies on genetic polymorphisms of the PR 
+ Indicates wild-type allele 
Mutation Allele Study 
Phenotype Associations 
FSH LH Estrogen Testosterone FAI TSH Insulin Follicle Count Hyperandrogenism PCO 
PROGINS T2 Karadeniz et al. ↓ - - - - - - - - - 
Table 6.3 Associations between genotypes of polymorphisms of the PR and phenotype among PCOS cases 
↑ represents a positive correlation 
↓ represents a negative correlation 
 
FSH = follicle-stimulating hormone 
LH = luteinizing hormone 
FAI = free androgen index 
TSH = thyroid-stimulating hormone 
PCO = polycystic ovaries
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DISCUSSION 
 
 There have been many studies on polycystic ovary syndrome since its initial 
discovery in 1935 on everything from clinical presentation to inheritance patterns to 
treatment recommendations. Studies on its genetic origins have been increasing rapidly 
over the last twenty years, and each study brings the literature one small step closer to 
understanding the genetic component of PCOS. Because the pathophysiology of PCOS is 
centered on aberrant function of the HPG axis, it is beneficial to search among this axis 
for possible genetic causes. Single-nucleotide polymorphisms (SNPs) of the receptors in 
the HPG axis were reviewed, as well as the AMHR2 receptor. Table 7.1 provides a 
summary of the receptor type and location, as well as each receptor’s location within the 
genome. There is hardly any organizational pattern, with the exception of the LHR and 
FSHR both being located at 2p16.3. 
Receptor 
Receptor 
Type 
Receptor Location 
Gene 
Location 
GnRHR GPCR plasma membrane of gonadotropes 4q13.2 
LHR GPCR 
plasma membrane of theca, granulosa, and 
luteal cells of ovary; plasma membrane of 
adipocytes 
2p16.3 
FSHR GPCR plasma membrane of granulosa cells of ovary 2p16.3 
AMHR2 TGFβ plasma membrane of granulosa cells of ovary 12q13.13 
ESR1 nuclear nucleus of various target cells 6q25.1-2 
ESR2 nuclear nucleus of various target cells 14q23.2-3 
PR nuclear nucleus of endometrial cells 11q22.1 
Table 7.1 Summary of the receptor type, location, and gene location 
 Analysis of polymorphisms of these receptors yielded much information and little 
consensus. Many receptors in the HPG axis have not been subjected to enough study to 
draw any sort of meaningful conclusion. Table 7.2 provides a summary of SNPs with 
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enough data to make preliminary inferences—a minimum of three studies was arbitrarily 
selected. Only the LHR, FSHR, and AMHR2 had enough repeated studies to fulfill this 
criteria. A polymorphism was said to have a possible etiologic role based on a simple 
majority of existing studies, primarily to keep things from becoming too complicated. A 
polymorphism was said to have a possible phenotypic role if any phenotypic associations 
were reported, since many studies did not attempt to assess this so therefore a simple 
majority would be unrepresentative. 
Receptor dbSNP 
SNP 
Location 
# Studies 
Etiologic 
Role 
Phenotypic 
Role 
LHR 
rs13405728 intron 6   
rs2293275 exon 10 5   
rs4539842 exon 1 3   
FSHR 
rs6165 exon 10 12   
rs6166 exon 10 10   
rs2268361 intron 8 3   
rs2349415 intron 3   
AMHR2 rs2002555 5’-UTR 3   
Table 7.2 Summary of the most tested SNPs 
 
Analysis of the LHR found three SNPs possibly associated with PCOS: 
rs13405728, rs2293275, and rs4539842. The rs13405728 SNP is located within an intron 
and results in an A>G transition. It was found to have a phenotypic role only. The 
rs2293275 SNP is located in exon 10 and results in a G>A transition at position 935 (935 
G>A), which causes an amino acid change from serine to asparagine at position 312 of 
the receptor protein. Both etiologic and phenotypic associations were found. The 
rs4539842 SNP is located in exon 1 and results in an insertion of nucleotides CTCCAG 
at position 54, which results in insertion of leucine and glutamine at position 18 in the 
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receptor protein. Only phenotypic relationships were found for this SNP, which suggests 
that the polymorphism is only involved in PCOS phenotype and does not have an 
etiologic role. 
Analysis of the FSHR found four SNPs possibly associated with PCOS: rs6165, 
rs6166, rs2268361, and rs2349415. The rs6165 SNP is located in exon 10 and results in 
an A>G transition at position 919 (919 A>G), which causes an amino acid change from 
threonine to alanine at position 307 in the receptor protein. The rs6166 SNP is also 
located in exon 10 and results in an A>G transition at position 2039 (2039 A>G), which 
causes an amino acid change from asparagine to serine at position 680 of the receptor 
protein. The rs2268361 SNP is located within intron 8 and results in a G>A transition. 
The rs2349415 SNP is located within an unspecified intron and results in a C>T 
transition at position 533 (533 C>T). Only rs2349415 was found to have an etiologic role 
in PCOS. All listed SNPs were found to have phenotypic roles. 
Analysis of the AMHR2 found only one SNP possibly associated with PCOS: 
rs2002555. This SNP is located in the 5’-UTR and results in an A>G transition at 
position 482 of the UTR (-482 A>G). This was found to have a phenotypic role only. 
Further research is obviously needed, both on the SNPs with possible etiologic and 
phenotypic associations in Table 7.2 as well as repeat studies on unlisted SNPs. 
 There are many limitations of these studies, as discussed throughout. The four 
main limitations are much the same throughout and deserve further examination and 
explanation. First, study sizes throughout are highly variable and generally fall on the 
small side. This is understandable from a financial perspective given the large expense of 
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candidate gene studies, but it makes it more difficult for true relationships to become 
apparent in an already heterogeneous study population. Other than general statistical 
power calculations, there are no methods specific to PCOS for assessment of study size. 
Furthermore, there are no available guidelines or standardized parameters on study sizes 
for PCOS candidate gene studies, nor have there been studies attempting to assess the 
differences in results based on number of participants. A study such as this would be 
extremely useful in developing a standardized study protocol for future research on the 
genetic origins of PCOS. It is necessary to approach the genetic studies of PCOS from 
this strict, standardized perspective because it is such a complex, heterogeneous disease. 
An analysis by Huang et al. (2015) among PCOS patients diagnosed by the 
Rotterdam criteria found that patients could be separated into four distinct categories 
based on symptoms for diagnosis: hyperandrogenism (HA), chronic anovulation, (AO) 
and PCO morphology. The four phenotypes are as follows: full PCOS (HA + AO + 
PCO); non-PCO (HA + AO); non-hyperandrogenic (AO + PCO); and ovulatory (HA + 
PCO). Participants in each phenotypic category were found to differ significantly on 
almost all anthropometric, endocrine, and metabolic characteristics (P < 0.001), 
quantitatively demonstrating the great variability in PCOS among participants diagnosed 
by a single set of clinical criteria (Huang et al, 2015). Thus, establishing a standardized 
protocol where participants are stratified into these four phenotypes would be hugely 
beneficial in obtaining more conclusive results. 
 Interconnected to the discussion on the findings of Huang et al. (2015) is the 
general issue of PCOS diagnosis criteria. Analyses are based on any of the three existing 
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diagnosis criteria, as well as some occasionally recruiting participants based on country-
specific criteria sets (i.e. criteria of the Japan Society of Obstetrics and Gynecology). It 
has previously been addressed how each set of diagnosis criteria differs and how these 
discrepancies affect the overall estimates of PCOS prevalence in the general population. 
The NIH criteria are the most stringent of the three, requiring clinical or biochemical 
hyperandrogenism and chronic anovulation for diagnosis. The prevalence of PCOS based 
on the NIH criteria is estimated to be 6%. The more lax Rotterdam criteria requires two 
of either oligo-anovulation, clinical/biochemical hyperandrogenism, or PCO morphology 
for diagnosis, and prevalence based on the Rotterdam criteria is estimated to be 10%. The 
more recent AE-PCOS Society criteria require clinical/biochemical hyperandrogenism 
plus either oligo-anovulation or PCO morphology. The prevalence of PCOS based on this 
set of diagnosis criteria is estimated to be 10% as well (Bozdag et al., 2016). Given the 
great variability between diagnosis criteria as well as within, as demonstrated by Huang 
et al. (2015), it is absolutely necessary to better elucidate a study protocol for PCOS 
patients. This could be accomplished through separating PCOS cases into the four 
phenotypic categories put forth by Huang et al. (2015) as much as possible, or even 
restricting the inclusion criteria to one of the four possible phenotypes of the Rotterdam 
criteria. Left uncategorized, the presumably heterogeneous PCOS subgroups could mask 
associations present among phenotypes and prevent true relationships from being 
realized. 
 Other limitations include the tendency to leave results unadjusted for potential 
confounding variables. These include age and BMI, as well as other possible 
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characteristics that have thus been unidentified. It has previously been mentioned that age 
and BMI are sources of genetic variability alone (Aunan et al., 2016; Xia et al., 2013), so 
leaving them unadjusted is a grave source of confounding. However, higher BMI is a 
secondary symptom of PCOS, so some researchers may be inclined to treat it as another 
continuous variable rather than a confounder. However, there have been a few recent 
studies to examine the relationship between BMI and endocrine characteristics in PCOS 
patients. A 2012 study among Saudi Arabian women examined the levels of LH, FSH, 
estrogen, dehydroepiandrosterone sulfate (DHEA-S), sex hormone-binding globulin 
(SHBG), testosterone, prolactin, progesterone, and LH/FSH ratio among PCOS cases and 
controls. They examined the results of the raw data as well as age- and BMI-adjusted data 
and found that there were very few differences between the unadjusted and adjusted 
results (Fakhoury et al., 2012). Alternatively, a recent study on genetic expression of 
AMH, AMHR, and androgen receptor (AR) in granulosa cells of PCOS cases and 
controls found that participants’ BMI was significantly correlated with expression in both 
study groups (Nouri et al., 2016). Another study by Mani et al. (2015) found that PCOS 
phenotype is significantly related to age and BMI in Caucasian and South Asian 
populations. These studies offer very little insight on the status of BMI as a confounder in 
PCOS research. Furthermore, there have been no studies that explicitly explore the 
genetic differences between normal-weight and overweight/obese PCOS patients, so at 
this point it is unsure whether BMI is a true confounding variable in PCOS. Until more is 
known about its effects among women with PCOS, it is necessary to treat it as a potential 
confounder and adjust for it. 
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 Lastly, the wide variability in ethnicity among existing studies is a major 
limitation of PCOS research. Not only does it limit the generalizability of the individual 
studies themselves, but also it creates barriers in replication among different ethnic 
populations since some polymorphisms may only be present in a single ethnic group. 
This has been found to be true in ailments like chronic liver disease (Pontoriero et al., 
2015) as well as many others. A study among Dutch PCOS patients and controls 
attempted to analyze the presence of SNPs identified in a GWAS among Chinese PCOS 
patients and were only able to confirm existence of 12 out of the 17 identified SNPs 
(Louwers et al., 2013). This suggests that SNPs identified in GWAS studies of PCOS 
performed among Chinese populations may not be generalizable to other ethnic groups 
because the SNPs do not exist in all populations. Furthermore, PCOS phenotype has been 
found to differ significantly depending on ethnicity with separate phenotypes for 
Caucasian, Hispanic, Black, South Asian, and East Asian populations (Mani et al., 2015; 
Engmann et al., 2017; and Huang et al., 2016). Also of note, Louwers et al. (2014) 
demonstrated that significant misclassification can arise if researchers rely on self-
reported ethnicity rather than a more precise method such as genetic ancestry data. 
 As the knowledge base on the genetic origins of PCOS expands, it is exciting to 
think of its potential uses for diagnosis, prevention, and treatment. Once the genetic 
markers of PCOS are known, it will be easy to perform a simple test to search for these 
markers. Discrepancy and debate over diagnosis criteria would be completely eliminated, 
as the disease could be diagnosed in a completely utilitarian method. Pre-pubescent girls 
with a family history of PCOS could be subjected to this same test in childhood to search 
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for these genetic markers in order to maintain strict control of BMI, as weight gain during 
puberty is often the inciting factor in development of PCOS. Finally, knowledge of each 
patient’s genetic mutations could help separate them into different phenotype categories 
and thus allow for more personalized treatment. 
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